You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

401 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    alectinib - Treatment of non-small cell lung cancer, according to specific criteria
Apr 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
New Drug Funding Program
    Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Nov 2024
Regimen
Intent: Palliative
Nov 2024
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
Aug 2024
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
New Drug Funding Program
    Raltitrexed - Metastatic Colorectal Small Bowel or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Metastatic Esophageal, Gastroesophageal Junction, or Gastric Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Raltitrexed - Adjuvant Esophageal, Gastroesophageal Junction, or Gastric Cancer
Jun 2024
Regimen
Regimen
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Jun 2024

Pages